SCHEMBL4117316

SCHEMBL4117316

Cn1nc(-c2cccnc2)c2nc(N(CCCN3CCOCC3)Cc3ccc(F)cc3)[nH]c(=O)c21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 2/20 0.43
MAPK12 P53778 2/20 0.43
MAPK11 Q15759 2/20 0.43
MAPK14 Q16539 2/20 0.43
GAA P10253 1/20 0.37
ALDH1A1 P00352 7/20 0.37
KDM4E B2RXH2 5/20 0.37
HSD17B10 Q99714 4/20 0.37
SMN1; SMN2 Q16637 4/20 0.37
HPGD P15428 3/20 0.37
ALOX15 P16050 1/20 0.37
MAPK1 P28482 1/20 0.37
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
ATM Q13315 1/20 0.36
USP2 O75604 2/20 0.35
PDE9A O76083 1/20 0.35
PDE1A P54750 1/20 0.35
PDE1B Q01064 1/20 0.35
PDE1C Q14123 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3996853 0.84 GAA (0.42) MAPK13MAPK12MAPK11MAPK14GAA
SCHEMBL4131950 0.82 GAA (0.41) MAPK13MAPK12MAPK11MAPK14GAA
SCHEMBL4125332 0.82 PDE5A (0.46) GAAALDH1A1KDM4EHSD17B10SMN1; SMN2
SCHEMBL4123921 0.75 PDE5A (0.42)
SCHEMBL4142307 0.73 PDE5A (0.47) GAAALDH1A1KDM4EHSD17B10HPGD
SCHEMBL4136563 0.69 PDE5A (0.43) GAAALDH1A1KDM4EHPGDPDE9A
SCHEMBL8041296 0.67 PDE5A (0.48) ALDH1A1HSD17B10HPGDMAPK1PDE1A
SCHEMBL4126045 0.66 PDE5A (0.41)
SCHEMBL3997198 0.65 ALDH1A1 (0.37) MAPK13MAPK12MAPK11MAPK14ALDH1A1
SCHEMBL4132815 0.65 KDM4E (0.41) ALDH1A1KDM4ESMN1; SMN2LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009071706-A1 PYRAZOLEPYRIMIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES GALAPAGOS NV (BE) 2009-06-11 WO disclosed